Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
LAVA Therapeutics ( (LVTX) ) has provided an announcement.
On September 30, 2025, LAVA Therapeutics announced the cancellation of its Extraordinary General Meeting (EGM) initially scheduled for the same day, which was intended to discuss a transaction with XOMA Royalty Corporation. The meeting will be rescheduled for early November 2025 to allow further discussions on the transaction’s terms, including cash forecasts and shareholder considerations. This delay aims to address potential liabilities and confirm the net cash to be delivered to shareholders, with the acquisition expected to close in the fourth quarter of 2025.
The most recent analyst rating on (LVTX) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on LAVA Therapeutics stock, see the LVTX Stock Forecast page.
Spark’s Take on LVTX Stock
According to Spark, TipRanks’ AI Analyst, LVTX is a Neutral.
The overall stock score is primarily impacted by the company’s weak financial performance, characterized by negative profitability and cash flow challenges. Technical analysis provides some positive momentum, but the valuation remains unattractive due to ongoing losses. The absence of earnings call data and corporate events limits additional insights.
To see Spark’s full report on LVTX stock, click here.
More about LAVA Therapeutics
LAVA Therapeutics N.V. is a biopharmaceutical company specializing in the development of clinical-stage bispecific gamma delta T cell engagers through its proprietary Gammabody® platform. The company focuses on targeting hematologic cancers and solid tumors, with partnerships including Johnson & Johnson and Pfizer.
Average Trading Volume: 197,735
Technical Sentiment Signal: Hold
Current Market Cap: $42.35M
For detailed information about LVTX stock, go to TipRanks’ Stock Analysis page.